Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $17.6300 (0.17%) ($17.3000 - $17.8300) on Wed. Jun. 5, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.2% (three month average) | RSI | 83 | Latest Price | $17.6300(0.17%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 0.6% a day on average for past five trading days. | Weekly Trend | IOVA advances 8.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) XBI(49%) ARKG(48%) IWO(44%) ARKK(42%) | Factors Impacting IOVA price | IOVA will decline at least -3.1% in a week (0% probabilities). VXX(-15%) UUP(-9%) IFRA(-6%) TLT(-2%) TBT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.1% (StdDev 6.2%) | Hourly BBV | 0 () | Intraday Trend | 0.2% | | | |
|
5 Day Moving Average | $17.49(0.8%) | 10 Day Moving Average | $17.3(1.91%) | 20 Day Moving Average | $15.15(16.37%) | To recent high | -2.3% | To recent low | 88% | Market Cap | $2.582b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |